Suppr超能文献

重组严重急性呼吸综合征冠状病毒刺突蛋白的抗原性及受体结合能力

Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein.

作者信息

Ho Tin-Yun, Wu Shih-Lu, Cheng Shin-Ei, Wei Yen-Chiao, Huang Shan-Ping, Hsiang Chien-Yun

机构信息

Institute of Chinese Medical Science, China Medical University, ROC, Taichung, Taiwan

出版信息

Biochem Biophys Res Commun. 2004 Jan 23;313(4):938-47. doi: 10.1016/j.bbrc.2003.11.180.

Abstract

Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a novel coronavirus and causing worldwide outbreaks. SARS coronavirus (SARS-CoV) is an enveloped RNA virus, which contains several structural proteins. Among these proteins, spike (S) protein is responsible for binding to specific cellular receptors and is a major antigenic determinant, which induces neutralizing antibody. In order to analyze the antigenicity and receptor-binding ability of SARS-CoV S protein, we expressed the S protein in Escherichia coli using a pET expression vector. After the isopropyl-beta-D-thiogalactoside induction, S protein was expressed in the soluble form and purified by nickel-affinity chromatography to homogeneity. The amount of S protein recovered was 0.2-0.3mg/100ml bacterial culture. The S protein was recognized by sera from SARS patients by ELISA and Western blot, which indicated that recombinant S protein retained its antigenicity. By biotinylated ELISA and Western blot using biotin-labeled S protein as the probe, we identified 130-kDa and 140-kDa proteins in Vero cells that might be the cellular receptors responsible for SARS-CoV infection. Taken together, these results suggested that recombinant S protein exhibited the antigenicity and receptor-binding ability, and it could be a good candidate for further developing SARS vaccine and anti-SARS therapy.

摘要

严重急性呼吸综合征(SARS)是一种与新型冠状病毒相关的新发传染病,曾在全球范围内爆发。SARS冠状病毒(SARS-CoV)是一种有包膜的RNA病毒,它含有几种结构蛋白。在这些蛋白中,刺突(S)蛋白负责与特定细胞受体结合,是主要的抗原决定簇,可诱导中和抗体。为了分析SARS-CoV S蛋白的抗原性和受体结合能力,我们使用pET表达载体在大肠杆菌中表达了S蛋白。经异丙基-β-D-硫代半乳糖苷诱导后,S蛋白以可溶性形式表达,并通过镍亲和层析纯化至均一性。回收的S蛋白量为0.2 - 0.3mg/100ml细菌培养物。通过ELISA和Western blot检测发现,SARS患者血清可识别该S蛋白,这表明重组S蛋白保留了其抗原性。以生物素标记的S蛋白为探针,通过生物素化ELISA和Western blot,我们在Vero细胞中鉴定出可能是负责SARS-CoV感染的细胞受体的130-kDa和140-kDa蛋白。综上所述,这些结果表明重组S蛋白具有抗原性和受体结合能力,可能是进一步研发SARS疫苗和抗SARS治疗药物的良好候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa5c/7111049/0a3ec9ce4eb3/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验